Qadri S M, Saldin H, Ueno Y
King Faisal Specialist Hospital and Research Centre Riyadh, Saudi Arabia.
Chemotherapy. 1993;39(1):55-8. doi: 10.1159/000238974.
In vitro response of 469 clinical isolates of gram-positive cocci was tested against MDL 62873 by the agar dilution method. The bacteria consisted of 407 isolates of staphylococci and 62 strains of enterococci. In vitro activity of MDL 62873 was compared with that of ampicillin, augmentin, erythromycin and vancomycin. All the isolates were completely inhibited by MDL 62873 at an MIC ranging between 0.25 and 8.0 micrograms/ml. In vitro activity of this new amide derivative of teicoplanin was far superior to that of ampicillin, augmentin and erythromycin and equal to or slightly better than that of vancomycin.
采用琼脂稀释法检测了469株革兰氏阳性球菌临床分离株对MDL 62873的体外反应。这些细菌包括407株葡萄球菌分离株和62株肠球菌菌株。将MDL 62873的体外活性与氨苄西林、奥格门汀、红霉素和万古霉素的体外活性进行了比较。所有分离株在0.25至8.0微克/毫升的最低抑菌浓度（MIC）下均被MDL 62873完全抑制。这种替考拉宁新酰胺衍生物的体外活性远优于氨苄西林、奥格门汀和红霉素，与万古霉素相当或略优于万古霉素。
